Tezacitabine

Drug Profile

Tezacitabine

Alternative Names: FMdc; KW 2331; MDL 101731

Latest Information Update: 22 Mar 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action Ribonucleoside triphosphate reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Viral infections

Most Recent Events

  • 22 Mar 2004 Discontinued - Phase-I for Solid tumours in Japan (IV)
  • 22 Mar 2004 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 22 Mar 2004 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top